WhiteOak Capital Pharma and Healthcare Fund Regular Growth
EquitySector - HealthcareVery High Risk
Regular
NAV (13-Mar-26)
Returns (Since Inception)
Fund Overview
Fund Size
₹533 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
About this fund
As of 13-Mar-26, it has a Net Asset Value (NAV) of ₹13.53, Assets Under Management (AUM) of 533.05 Crores, and an expense ratio of 2.38%.
- WhiteOak Capital Pharma and Healthcare Fund Regular Growth has given a CAGR return of 15.50% since inception.
- The fund's asset allocation comprises around 98.70% in equities, 0.00% in debts, and 1.30% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+11.70%
+9.79% (Cat Avg.)
Since Inception
+15.50%
— (Cat Avg.)
Portfolio Summaryas of 28th February 2026
| Equity | ₹526.1 Cr | 98.70% |
| Others | ₹6.95 Cr | 1.30% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹63.15 Cr | 11.85% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹50.34 Cr | 9.44% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹31.33 Cr | 5.88% |
| Fortis Healthcare Ltd | Equity | ₹29.54 Cr | 5.54% |
| Lupin Ltd | Equity | ₹28.18 Cr | 5.29% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹27.08 Cr | 5.08% |
| Cash Offset For Derivatives | Cash - General Offset | ₹-25.72 Cr | 4.83% |
| Divi's Laboratories Ltd | Equity | ₹25.27 Cr | 4.74% |
| Laurus Labs Ltd | Equity | ₹23.06 Cr | 4.33% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹21.06 Cr | 3.95% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹15.92 Cr | 2.99% |
| Sai Life Sciences Ltd | Equity | ₹13.14 Cr | 2.46% |
| Ajanta Pharma Ltd | Equity | ₹12.52 Cr | 2.35% |
| Corona Remedies Ltd | Equity | ₹12.32 Cr | 2.31% |
| Acutaas Chemicals Ltd | Equity | ₹12.01 Cr | 2.25% |
| Aurobindo Pharma Limited | Equity - Future | ₹10.6 Cr | 1.99% |
| Ipca Laboratories Ltd | Equity | ₹10.46 Cr | 1.96% |
| Narayana Hrudayalaya Ltd | Equity | ₹10.32 Cr | 1.94% |
| Shaily Engineering Plastics Ltd | Equity | ₹9.51 Cr | 1.78% |
| Pfizer Ltd | Equity | ₹9.23 Cr | 1.73% |
| Emcure Pharmaceuticals Ltd | Equity | ₹9.05 Cr | 1.70% |
| Navin Fluorine International Ltd | Equity | ₹8.52 Cr | 1.60% |
| AstraZeneca Pharma India Ltd | Equity | ₹7.88 Cr | 1.48% |
| Neuland Laboratories Ltd | Equity | ₹7.78 Cr | 1.46% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹7.03 Cr | 1.32% |
| Aurobindo Pharma Ltd | Equity | ₹7.02 Cr | 1.32% |
| Aether Industries Ltd | Equity | ₹6.73 Cr | 1.26% |
| Strides Pharma Science Ltd | Equity | ₹6.27 Cr | 1.18% |
| Dr. Lal PathLabs Ltd | Equity | ₹6.26 Cr | 1.17% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹6.1 Cr | 1.14% |
| Thyrocare Technologies Ltd | Equity | ₹5.28 Cr | 0.99% |
| Dr. Reddy's Laboratories Limited | Equity - Future | ₹5.09 Cr | 0.96% |
| Tbills | Bond - Gov't/Treasury | ₹4.94 Cr | 0.93% |
| Divi's Laboratories Limited | Equity - Future | ₹4.7 Cr | 0.88% |
| Supriya Lifescience Ltd | Equity | ₹4.46 Cr | 0.84% |
| Sudeep Pharma Ltd | Equity | ₹4.02 Cr | 0.75% |
| 12/03/2026 Maturing 91 DTB | Bond - Gov't/Treasury | ₹3.99 Cr | 0.75% |
| Net Receivables / (Payables) | Cash - Collateral | ₹3.94 Cr | 0.74% |
| Zota Health Care Ltd | Equity | ₹3.5 Cr | 0.66% |
| Aarti Pharmalabs Ltd | Equity | ₹3.25 Cr | 0.61% |
| Abbott India Ltd | Equity | ₹3.1 Cr | 0.58% |
| Alkem Laboratories Ltd | Equity | ₹2.9 Cr | 0.54% |
| Shilpa Medicare Ltd | Equity | ₹2.78 Cr | 0.52% |
| Zydus Lifesciences Ltd | Equity | ₹2.62 Cr | 0.49% |
| Max Healthcare Institute Limited | Equity - Future | ₹2.48 Cr | 0.46% |
| Apollo Hospitals Enterprise Limited | Equity - Future | ₹1.86 Cr | 0.35% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.78 Cr | 0.33% |
| Torrent Pharmaceuticals Ltd | Equity | ₹1.55 Cr | 0.29% |
| Poly Medicure Ltd | Equity | ₹1.55 Cr | 0.29% |
| Orchid Pharma Ltd | Equity | ₹1.38 Cr | 0.26% |
| Tatva Chintan Pharma Chem Ltd | Equity | ₹1.07 Cr | 0.20% |
| 19/03/2026 Maturing 364 DTB | Bond - Gov't/Treasury | ₹1 Cr | 0.19% |
| 07/05/2026 Maturing 364 DTB | Bond - Gov't/Treasury | ₹0.99 Cr | 0.19% |
| Tbills | Bond - Gov't/Treasury | ₹0.99 Cr | 0.19% |
| 19/03/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹0.7 Cr | 0.13% |
| Sun Pharmaceutical Industries Limited | Equity - Future | ₹0.55 Cr | 0.10% |
| Fortis Healthcare Limited | Equity - Future | ₹0.44 Cr | 0.08% |
| 09/04/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹0.2 Cr | 0.04% |
Allocation By Market Cap (Equity)
Large Cap Stocks
27.84%
Mid Cap Stocks
21.98%
Small Cap Stocks
44.05%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹462.53 Cr | 86.77% |
| Basic Materials | ₹37.84 Cr | 7.10% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.02%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.11
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.01
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Trupti Agrawal
Since May 2025
Dheeresh Pathak
Since February 2024
Ashish Agrawal
Since January 2025
Additional Scheme Detailsas of 28th February 2026
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹533 Cr | Age 2 years 1 month | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
About the AMC
WhiteOak Capital Mutual Fund
Total AUM
₹32,686 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Other Funds by WhiteOak Capital Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Regular Growth?
- Piyush Baranwal
- Ramesh Mantri
- Trupti Agrawal
- Dheeresh Pathak
- Ashish Agrawal
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
